DMAC
DiaMedica Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.75
+2.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 29.3M | 24.6M | 19.1M | 13.1M | 7.8M |
| SG&A Expense | 9.9M | 9.8M | 7.6M | 8.2M | 6.2M |
| General & Admin Expense | 9.9M | 9.8M | 7.6M | 8.2M | 6.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (366.0K) | — | — | — | — |
| Total Operating Expenses | 38.9M | 34.4M | 26.7M | 21.3M | 14.0M |
| Cost and Expenses | 38.9M | 34.4M | 26.7M | 21.3M | 14.0M |
| Operating Income (EBIT) | (38.9M) | (34.4M) | (26.7M) | (21.3M) | (14.0M) |
| Non-Operating | |||||
| Interest Income | — | — | 2.3M | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | 2.3M | — | — |
| Other Non-Op Income/Expense | 1.3M | 1.7M | 2.3M | 1.9M | 353.0K |
| Non-Operating Income (excl Interest) | (1.3M) | (1.7M) | (2.3M) | (1.9M) | (353.0K) |
| EBT (Pre-Tax Income) | (37.5M) | (32.7M) | (24.4M) | (19.3M) | (13.6M) |
| Income Tax Expense | 16.0K | 28.0K | 30.0K | 43.0K | 28.0K |
| Bottom Line | |||||
| Net Income | (37.5M) | (32.8M) | (24.4M) | (19.4M) | (13.7M) |
| Earnings from Cont. Ops | (37.5M) | (32.8M) | (24.4M) | (19.4M) | (13.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (37.5M) | (32.8M) | (24.4M) | (19.4M) | (13.7M) |
| Per Share | |||||
| Basic EPS | ($0.72) | ($0.70) | ($0.60) | ($0.60) | ($0.52) |
| Diluted EPS | ($0.72) | ($0.70) | ($0.60) | ($0.60) | ($0.52) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 53.9M | 47.0M | 40.4M | 32.6M | 26.4M |
| Diluted Shares Outstanding | 53.9M | 47.0M | 40.4M | 32.6M | 26.4M |
| Profitability Metrics | |||||
| EBITDA | (37.1M) | (32.7M) | (24.4M) | (19.3M) | (13.6M) |
| D&A | 422.0K | 43.0K | 39.0K | 30.0K | 25.0K |
| EBIT | (37.5M) | (32.7M) | (24.4M) | (19.3M) | (13.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026